Table 3.
Antitumor activity of sunvozertinib in patients with previously treated EGFRexon20ins NSCLC
| 50 mg | 100 mg | 200 mg | 300 mg | 400 mg | Total | |
|---|---|---|---|---|---|---|
| (n = 3) | (n = 2) | (n = 11) | (n = 31) | (n = 9) | (n = 56) | |
| Best response, n (%) | ||||||
| PR (unconfirmed) | 0 (0.0) | 1 (50.0) | 5 (45.5) | 15 (48.4) | 2 (22.2) | 23 (41.1) |
| PR (confirmed) | 0 (0.0) | 1 (50.0) | 5 (45.5) | 13 (41.9) | 2 (22.2) | 21 (37.5) |
| Stable disease | 2 (66.7) | 1 (50.0) | 4 (36.4) | 15 (48.4) | 5 (55.5) | 27 (48.2) |
| Progressive disease | 1 (33.3) | 0 (0.0) | 2 (18.2) | 3 (9.7) | 2 (22.2) | 8 (14.3) |
| Confirmed ORR, n (%) | 0 (0.0) | 1 (50.0) | 5 (45.5) | 13 (41.9) | 2 (22.2) | 21 (37.5) |
| Disease control rate, n (%) | 2 (66.7) | 2 (100.0) | 9 (81.8) | 28 (90.3) | 7 (77.7) | 48 (85.7) |
NOTE: Pooled data from WU-KONG1 and WU-KONG2 studies. Data cutoff date: April 3, 2021. Tumor response was assessed by investigators.